A combination of imaging tests conducted six to eight weeks after patients complete chemoradiotherapy for head and neck cancer may help identify patients who will respond to treatment and those who will require surgical follow-up, according to a report in the Archives of Otolaryngology–Head & Neck Surgery.
During the past two decades, chemoradiotherapy—combining chemotherapy and radiation treatments—has become important in helping preserve organs while treating advanced head and neck cancers. “These non-surgical approaches produce an excellent response at the primary tumor site and cervical lymph nodes resulting in high rates of locoregional disease control,” the authors write. “Accurate and timely assessment of disease response at the primary tumor site and cervical lymph nodes after chemoradiotherapy is essential to detect residual disease, to direct surgical salvage and to prevent tumor recurrence.”
James P. Malone, M.D., of the Southern Illinois School of Medicine, Springfield, and colleagues analysed 31 patients with advanced-stage head and neck cancer who were treated with chemoradiotherapy between 2004 and 2006. All patients underwent combined positron emission tomography and computed tomography (PET-CT) to detect evidence of persistent tumours six to eight weeks after the completion of treatment and then were tracked for a median of 24 months.
Assessing the response of the tumour to treatment with PET-CT had a sensitivity (rate of true positives) of 83 percent, specificity (rate of true negatives) of 54 percent, positive predictive value (probability that patients who test positive have the disease) of 31 percent and negative predictive value (probability that patients who test negative do not have the disease) of 92 percent.
In the 21 patients whose disease had spread to surrounding lymph nodes before treatment, sensitivity was 75 percent; specificity, more than 94 percent; positive predictive value, more than 75 percent; and negative predictive value, 94 percent. For the ten whose cancer was located in the neck only, specificity was 92 percent and negative predictive value more than 92 percent.
“On the basis of this study, PET-CT performed six to eight weeks after the completion of intra-arterial chemoradiotherapy for advanced squamous cell carcinoma of the head and neck is a valuable tool for measuring treatment response and facilitating clinical decision making,” they conclude. “In addition to early prediction of treatment response, PET-CT provides early detection of distant metastases, which permits earlier intervention in patients with distant disease. Further investigations of PET-CT in homogenously treated patient populations with consistent timing of post-treatment scans are necessary to more clearly elucidate the role of this imaging modality in the management of advanced squamous cell carcinoma of the head and neck.”
Journal reference: Arch Otolaryngol Head Neck Surg. 2009;135:1119-1125
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.